newsfilter
← Latest News
GlobeNewswire·

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug